USPTO serial 98844592
RESQ PHARMA
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- EINSTEIN, MATTHEW T
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with RESQ PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chicago, IL, US
Chicago, IL, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Hillary E. Maynard
Hillary E. Maynard Polsinelli PCPO Box 140310Kansas City, MO 64114-0310United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe and set for administering the lipid emulsion, all for use in treating anesthetic and drug toxicity; Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe and set for administering the lipid emulsion, all for use in resuscitating patients; Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe and set for administering the lipid emulsion, all for use in treating cardiac arrest due to ischemia and cardiac failure; syringes that are used for administering lipid emulsions in the nature of syringes sold filled with a pharmaceutical, namely, a lipid emulsion for use in treating anesthetic and drug toxicity, treating neurological toxicity, treating cardiac arrest due to ischemia, treating cardiac failure, treating cardiac toxicity, and for resuscitating patients | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 5, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 4, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 4, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 4, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 30, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 29, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 29, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 29, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 12, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 17, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 17, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 13, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 13, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 13, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 13, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 13, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 7, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 4, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 8, 2024 | NWAP | NEW APPLICATION ENTERED | — |